Histochemical characterization of non-neuroendocrine tumors and neuroendocrine cell hyperplasia induced in hamster lung by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone with or without hyperoxia.
Lung tumors induced by 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK) with or without hyperoxia have frequent K-ras mutations but only rare p53 mutations, suggesting that this may be a model for non-small cell lung cancers. The goals of the present study were (1) to characterize the histopathology of lung tumors induced in hamsters by NNK with or without O2 and (2) as a corollary, to quantitate the pulmonary neuroendocrine cell hyperplasia in the different treatment groups early and late in the treatment period. Lung tumors induced by NNK with or without O2 were 71% adenomas, 22% adenocarcinomas, approximately 4% bronchoalveolar carcinomas, and approximately 4% squamous/adenosquamous carcinomas. One-half of all tumors were positive for the Clara cell antigen CC10 and 21% of NNK-induced tumors were mucin positive, compared with 2% of NNK/O2-induced tumors (P = 0.003). Immunostaining for PGP9.5 was positive in 5% of tumors induced by NNK alone, but in none of NNK/O2-induced tumors (P = 0.024). Abundant proliferating cell nuclear antigen occurred in 55% of NNK-induced tumors, compared with 19% of NNK/O2-induced tumors (P = 0.009). These data indicate that NNK with or without O2 induces non-neuroendocrine lung tumors. Hyperoxia appears to inhibit cell proliferation and suppress mucinous and partial neuroendocrine differentiation in some of these tumors.
Sunday
M E
ME
Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Willett
C G
CG
Graham
S A
SA
Oreffo
V I
VI
Linnoila
R I
RI
Witschi
H
H
D000818:Animals; D002273:Carcinogens / Q000494:pharmacology; D006224:Cricetinae; D006651:Histocytochemistry; D006965:Hyperplasia; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000139:chemically induced* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008647:Mesocricetus; D009490:Neurosecretory Systems / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D009602:Nitrosamines / Q000494:pharmacology*; D010100:Oxygen / Q000378:metabolism*
D002273:Carcinogens; D009602:Nitrosamines; C016583:4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; D010100:Oxygen